{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluticasone+Furoate%2F+Vilanterol+100%2F25+mcg",
    "query": {
      "intervention": "Fluticasone Furoate/ Vilanterol 100/25 mcg"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 25,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluticasone+Furoate%2F+Vilanterol+100%2F25+mcg&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T08:36:04.915Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01957163",
      "title": "Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "FF",
          "type": "DRUG"
        },
        {
          "name": "VI",
          "type": "DRUG"
        },
        {
          "name": "UMEC",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 619,
      "start_date": "2013-10-01",
      "completion_date": "2014-04-01",
      "has_results": true,
      "last_update_posted_date": "2017-11-09",
      "last_synced_at": "2026-10-10T08:36:04.915Z",
      "location_count": 13,
      "location_summary": "Jasper, Alabama • Clearwater, Florida • Tampa, Florida + 10 more",
      "locations": [
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01957163"
    },
    {
      "nct_id": "NCT03474081",
      "title": "A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "FF/UMEC/VI",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Albuterol/salbutamol",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match FF/UMEC/VI",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match tiotropium",
          "type": "DRUG"
        },
        {
          "name": "ELLIPTA inhaler",
          "type": "DEVICE"
        },
        {
          "name": "HANDIHALER",
          "type": "DEVICE"
        },
        {
          "name": "MDI",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 800,
      "start_date": "2018-03-29",
      "completion_date": "2019-07-17",
      "has_results": true,
      "last_update_posted_date": "2021-07-15",
      "last_synced_at": "2026-10-10T08:36:04.915Z",
      "location_count": 33,
      "location_summary": "Andalusia, Alabama • Huntington Beach, California • Sacramento, California + 29 more",
      "locations": [
        {
          "city": "Andalusia",
          "state": "Alabama"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Simi Valley",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03474081"
    },
    {
      "nct_id": "NCT01686633",
      "title": "An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Fluticasone Furoate/ Vilanterol 200/25 mcg",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Furoate/ Vilanterol 100/25 mcg",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Furoate 100 mcg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1040,
      "start_date": "2012-09-20",
      "completion_date": "2013-10-15",
      "has_results": true,
      "last_update_posted_date": "2018-01-24",
      "last_synced_at": "2026-10-10T08:36:04.915Z",
      "location_count": 37,
      "location_summary": "Little Rock, Arkansas • Huntington Beach, California • Los Angeles, California + 33 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01686633"
    },
    {
      "nct_id": "NCT01336608",
      "title": "A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Fluticasone Furoate/Vilanterol",
          "type": "DRUG"
        },
        {
          "name": "Vilanterol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 446,
      "start_date": "2011-03-04",
      "completion_date": "2014-11-04",
      "has_results": true,
      "last_update_posted_date": "2017-11-08",
      "last_synced_at": "2026-10-10T08:36:04.915Z",
      "location_count": 36,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Newport Beach, California + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01336608"
    },
    {
      "nct_id": "NCT01957150",
      "title": "Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Fluticasone Furoate/Vilanterol",
          "type": "DRUG"
        },
        {
          "name": "Vilanterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 283,
      "start_date": "2014-01-28",
      "completion_date": "2018-03-26",
      "has_results": true,
      "last_update_posted_date": "2019-04-10",
      "last_synced_at": "2026-10-10T08:36:04.915Z",
      "location_count": 17,
      "location_summary": "Jasper, Alabama • Phoenix, Arizona • Fort Lauderdale, Florida + 14 more",
      "locations": [
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01957150"
    },
    {
      "nct_id": "NCT01453023",
      "title": "Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Fluticasone Furoate",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Furoate/Vilanterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "5 Years to 11 Years"
      },
      "enrollment_count": 26,
      "start_date": "2011-10",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2017-01-11",
      "last_synced_at": "2026-10-10T08:36:04.915Z",
      "location_count": 1,
      "location_summary": "Huntington Beach, California",
      "locations": [
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01453023"
    },
    {
      "nct_id": "NCT01894386",
      "title": "Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "FF 400 mcg",
          "type": "DRUG"
        },
        {
          "name": "UMEC 500 mcg",
          "type": "DRUG"
        },
        {
          "name": "UMEC 250 mcg",
          "type": "DRUG"
        },
        {
          "name": "VI 100 mcg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 48,
      "start_date": "2013-07-15",
      "completion_date": "2013-09-26",
      "has_results": false,
      "last_update_posted_date": "2017-05-15",
      "last_synced_at": "2026-10-10T08:36:04.915Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01894386"
    },
    {
      "nct_id": "NCT03248128",
      "title": "Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "FF/VI via ELLIPTA DPI",
          "type": "DRUG"
        },
        {
          "name": "FF via ELLIPTA DPI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 906,
      "start_date": "2017-10-20",
      "completion_date": "2022-03-21",
      "has_results": true,
      "last_update_posted_date": "2025-06-22",
      "last_synced_at": "2026-10-10T08:36:04.915Z",
      "location_count": 49,
      "location_summary": "Hoover, Alabama • Little Rock, Arkansas • Huntington Beach, California + 38 more",
      "locations": [
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03248128"
    },
    {
      "nct_id": "NCT01323621",
      "title": "Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Propionate 250mcg / salmeterol 50mcg",
          "type": "DRUG"
        },
        {
          "name": "Double-dummy placebo",
          "type": "DRUG"
        },
        {
          "name": "Salbutamol as needed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 512,
      "start_date": "2011-03-18",
      "completion_date": "2012-01-24",
      "has_results": true,
      "last_update_posted_date": "2018-02-15",
      "last_synced_at": "2026-10-10T08:36:04.915Z",
      "location_count": 13,
      "location_summary": "Jasper, Alabama • Riverside, California • DeLand, Florida + 10 more",
      "locations": [
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Coeur d'Alene",
          "state": "Idaho"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01323621"
    },
    {
      "nct_id": "NCT02301975",
      "title": "An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler",
          "type": "DRUG"
        },
        {
          "name": "Placebo inhalation powders via ELLIPTA inhaler",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler",
          "type": "DRUG"
        },
        {
          "name": "Placebo inhalation powder via ACCUHALER/DISKUS inhaler",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1526,
      "start_date": "2015-03-01",
      "completion_date": "2016-11-25",
      "has_results": true,
      "last_update_posted_date": "2018-08-06",
      "last_synced_at": "2026-10-10T08:36:04.915Z",
      "location_count": 34,
      "location_summary": "Huntington Beach, California • Riverside, California • Rolling Hills Estates, California + 30 more",
      "locations": [
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02301975"
    }
  ]
}